Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rick Gilfillan Leaving CMS Innovation Center By June 30

This article was originally published in The Gray Sheet

Executive Summary

Gilfillan, who is the first director of CMS’ Center for Medicare and Medicaid Innovation, will leave CMS by the end of June after almost three years at the helm of the center established in 2010 to experiment with and help implement new health care delivery and payment models.

You may also be interested in...

People In The News: Former Federal Officials On The Move; Changes At Aurinia, Neo, Mallinckrodt, Lilly, And More

Former FDA Commissioner and CMS Administrator Mark McClellan joins the Johnson & Johnson board; former CMS officials Larry Kocot, Mark Hamelburg and Thomas Hutchinson join law firm Epstein Becker & Green; ONCHIT head Farzad Mostashari heads to Brookings; Aurinia names Glickman acting CEO; more personnel moves in this month’s column.

People Briefs: Elekta, Zeltiq And Nonin Make Appointments; Gilfillan Goes To CHE Trinity Health

Elekta appoints president and CEO. Former Conceptus CEO D. Keith Grossman joins Zeltiq board. Former Center for Medicare and Medicaid Innovation Director Richard Gilfillan will head CHE Trinity Health. More people news.

CMS Responds To Pioneer ACO Concerns About Meeting Quality Measures

CMS says it will expect Pioneer ACOs to meet quality performance benchmarks in 2013 based on actual Medicare fee-for-service and Medicare Advantage performance data. The ACOs had requested a delay.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts